INTRODUCTION {#sec1-1}
============

Polycystic ovarian syndrome (PCOS) is the most common endocrinopathy of women with a prevalence of 6-10% based on the National Institute of Health criteria and as high as 15% when the broader Rotterdam criteria are applied.\[[@ref1]\] Obesity has reached it epidemic proportion. Its is present in 40-60% of women with PCOS mostly of central type.\[[@ref2][@ref3][@ref4]\] Weight loss is the first-line treatment evidence-based approach in overweight PCOS women.\[[@ref4]\]

Pharmacotherapy aiming to achieve weight loss for the group of obese PCOS patients comprises use of insulin-sensitizing drugs such as metformin and use of antiobesity drugs like orlistat.

There have been few randomized studies, which have compared the effects of orlistat and metformin in obese PCOS patients and have generally reported favorable results with equal efficacy of both drugs on weight reduction.\[[@ref5][@ref6][@ref7]\] Orlistat being long acting and gastric lipase inhibitor which prevent the hydrolysis of dietary fat into absorbable free fatty acids and monoglyceride with increase of fecal fat excretion. Metformin insulin sensitizers various other mechanisms have been proposed. Therefore in our study, we attempted to evaluate the role of orlistat in PCOS.

Methods {#sec2-1}
-------

The present study is a randomized controlled trial, which was carried out between October 2011 and June 2012 at Manipal Assisted Reproduction Center, Kasturba Medical College, Manipal University, Manipal (Karnataka).

Study population {#sec2-3}
----------------

The study population consisted of 90 overweight and obese women who fulfilled the criteria mentioned below were enrolled with 30 in each, orlistat, and metformin and control group.

Using a two-tailed alpha value (0.05) and a beta value (0.2) 30 observation per group would be sufficient to detect a significance difference.

Inclusion criteria {#sec2-4}
------------------

Age: \<40 years, body mass index (BMI): ≥23 (taken as cut-off for overweight in the study as per the recommendations\[[@ref8][@ref9][@ref10]\]), euthyroid, PCOS patients after a full work up done for infertility. Good antral follicles were taken into consideration for the study even though some women were nearing 40 years of age.

The diagnosis of PCOS was made according to the revised 2003 Rotterdam criteria.

Exclusion criteria {#sec2-5}
------------------

Male factorUntreated hypothyroidismRenal or hepatic impairmentMalabsorption syndromeDiabetes (type 2 or type 1).

Study design {#sec2-6}
------------

This was a randomized controlled clinical trial. All patients enrolled were randomly assigned to orlistat (Reshape, Meyer Organics), metformin (Obimet, Abbott), or control groups. Randomization was done by block randomization.

All overweight and obese infertile PCOS women were recruited in the study and randomized to receive either of the two drugs (orlistat or metformin) in combination with lifestyle interventions or as controls where they received lifestyle interventions alone. BMI was based on an adapted version for Asians.

Drug formulation {#sec2-7}
----------------

Patients in the metformin arm received the drug with fertility fitness program. Metformin was incremented stepwise to maximum 500 mg 3 times a day.

In orlistat arm subjects received orlistat in a standard dose of 120 mg twice a day and underwent fertility fitness program.

The control arm patients underwent fertility fitness program only.

Fertility fitness program {#sec2-8}
-------------------------

All subjects in the three arms were given specific hypocaloric dietary advice according to their weight and fertility fitness program was part of the treatment in all the groups. The fertility fitness program included diet, exercise and lifestyle modification.

Dietetic treatment {#sec2-9}
------------------

Dietary management was targeted for gradual weight loss (0.5-1 kg/week) through energy intake reduction and increasing physical activity with daily calorie intake between 1200 and 1800 kcal/day depending on their activity and BMI. Diet was composed of low fat 25% of energy moderate protein of 15% of energy and high carbohydrate intake of 55% of energy with increased consumption of fiber whole grain bread, cereals, fruits and vegetables.

Physiotherapy {#sec2-10}
-------------

Exercise was advised by a physiotherapiest. Total duration of exercise was around 1 h/day. It included warm up session, aerobic exercise session and cooled down session.

Ethical committee {#sec2-11}
-----------------

Ethical committee clearance was done.

Methodology {#sec2-12}
-----------

### At the first visit following were performed {#sec3-1}

**History**

Menstrual cyclicity and the presence or absence of hirsutism and acne.

**Physical examination**

Body mass index (was taken as the adapted version for Asian people), waist circumference, waist-hip ratio. Waist circumference was measured as the smallest measurement between the iliac crest and the 12^th^ rib.

**Endocrine profile**

Baseline serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) (Roche Co.): Performed on day 2 of the spontaneous cycle or progesterone-induced withdrawal bleed.

**Androgen profile**

Total testosterone, dehydroepiandrosterone sulfate (DHEAS), sex hormone-binding globulin (SHBG) and free androgen index (FAI). The FAI was calculated from the following formula: (Total testosterone/SHBG) × 100. Androgen estimation was done by immuno electric chermluminence method (ng/ml).

Parameters for measuring insulin resistance - Fasting insulin, fasting glucose and homeostatic model assessment insulin resistance (HOMA-IR).

Lipid profile - High-density lipoprotein, low-density lipoprotein (LDL), total cholesterol, triglycerides. Lipid profile was estimated by ELISA (mg/dl).

Transvaginal ultrasonography {#sec2-13}
----------------------------

### Follow-up visits {#sec3-2}

The following were recorded at 4 weekly intervals for 3 months-history and physical examination, especially anthropometric evaluation.

At study conclusion {#sec2-14}
-------------------

At 12 weeks follow-up, androgen profile, serum LH and FSH, lipid profile, fasting insulin, and fasting blood sugar were repeated.

Subjects who ovulated spontaneously (by ultrasound) were advised timed intercourse and were evaluated for pregnancy for a period of 3 months.

The subjects who did not have spontaneous ovulation as observed by ultrasound underwent one cycle of ovulation induction with clomiphene citrate 50 mg from day 2 to day 6 of the cycle.

Transvaginal sonography was done on day 2 for antral follicle count for ovarian reserve and following ovulation induction for follicular monitoring.

At least two follicles with a size of 18 mm were considered to be a good response and if less poor response. Those who responded to one cycle of ovulation induction underwent intrauterine insemination.

Outcome measures {#sec2-15}
----------------

### Primary outcome measures {#sec3-3}

OvulationWeight loss

### Secondary outcome measures {#sec3-4}

Change in the BMI and waist circumference, predictors of response to treatment (ovulation, detected by ultrasound) for the three arms.

Statistical analysis {#sec2-16}
--------------------

Statistical analysis was performed using the SPSS program for Windows, version 17.0 (SPSS Chicago, Illinious, USA). For all statistical tests, a *P* \< 0.05 was taken to indicate a significant difference. Continuous variables are presented as mean ± standard error, and categorical variables are presented as absolute numbers and percentage. Data were checked for normality before statistical analysis using Shapiro-Wilk test. Normally distributed continuous variables were compared using ANOVA. If the *F* value was significant and variance was homogeneous, Bonferroni multiple comparison test was used to assess the differences between the individual groups; otherwise, Tamhane\'s T2 test was used. The Kruskal-Wallis test was used for those variables that were not normally distributed and further complications were done using Mann-Whitney U-test. Categorical variables were analyzed using the Chi-square test. For all statistical tests, a *P* \< 0.05 was taken to indicate a significant difference.

RESULTS {#sec1-2}
=======

The baseline demographic and clinical characteristics were similar in three groups with no significant difference. The mean age, clinical characteristics such as menstrual history, androgenic symptoms, weight, BMI, waist circumference, waist-hip ratio were comparable in three groups.

Primary outcome {#sec2-17}
---------------

### Ovulation rates {#sec3-5}

Subjects in orlistat and metformin arms had similar ovulation rates which were significantly better than that of the control group with *P* - 0.008 as shown [Table 1](#T1){ref-type="table"}.

###### 

Comparison of ovulation rate in three groups

![](JHRS-7-255-g001)

### Conception rates {#sec3-6}

As shown in [Table 2](#T2){ref-type="table"}, 12 participants (40%) conceived in orlistat group, 8 (16.7%) participants conceived in the metformin arm and 1 (3.3%) participant conceived in the control arm (*P* - 0.003).

###### 

Comparison of conception rates in three groups

![](JHRS-7-255-g002)

### Weight loss {#sec3-7}

**Comparisons within group**

Over the course of the study, there was overall statistically significant fall in all anthropometric measurements in the three groups with *P* \< 0.001 as highlighted in Figures [1](#F1){ref-type="fig"}--[3](#F3){ref-type="fig"}.

![Graph showing weight in the three arms at follow-up visits](JHRS-7-255-g003){#F1}

![Graph showing body mass index in the three arms at follow-up visits](JHRS-7-255-g004){#F2}

![Graph showing waist circumference in the three arms at follow-up visits](JHRS-7-255-g005){#F3}

[Figure 1](#F1){ref-type="fig"} shows a significant fall in weight over 3 months in all three groups, but fall is significantly more in two drug arms.

[Figure 2](#F2){ref-type="fig"} shows a significant decrease in BMI over 3 months in all three groups, but fall is more in two drug arms compared with control arm.

### Between groups comparisons {#sec3-8}

Both drug arms have similar efficacy in reducing weight, BMI, waist circumference and waist-hip ratio as highlighted in [Table 3](#T3){ref-type="table"}.

###### 

Percentage change in parameters for measuring weight loss at follow-up between the groups

![](JHRS-7-255-g006)

Secondary outcome {#sec2-18}
-----------------

### Androgen profile {#sec3-9}

**Comparisons within groups**

As shown in [Table 4](#T4){ref-type="table"} in all the arms, there was a significant reduction in testosterone, FAI by the end of 12 weeks whereas there was no significant change in SHBG or DHEAS levels.

###### 

Percentage change in androgen profile at follow-up between three groups

![](JHRS-7-255-g007)

**Comparisons between groups**

There was no significant difference in the mean serum testosterone, DHEAS, SHBG concentrations or FAI between the three arms at the start and end of the study as shown in [Table 4](#T4){ref-type="table"}.

### Lipid profile {#sec3-10}

**Comparisons within group**

As summarized in [Table 5](#T5){ref-type="table"}, the levels of total cholesterol, LDL, triglycerides decreased significantly in orlistat arm.

###### 

Percentage change in lipid profile at follow-up between the three groups

![](JHRS-7-255-g008)

**Comparisons between groups**

Metformin and control arm orlistat showed significant improvement in LDL, triglycerides and total cholesterol at the start and end of the study as depicted in [Table 5](#T5){ref-type="table"}.

### Endocrine profile {#sec3-11}

**Comparisons within group**

As shown in [Table 6](#T6){ref-type="table"}, the groups showed no significant improvement in the biochemical parameters for assessing insulin resistance except metformin group but it did not reach the level of significance.

###### 

Percentage change in endocrine profile of insulin resistance

![](JHRS-7-255-g009)

**Comparsions between groups**

As shown in [Table 6](#T6){ref-type="table"}, there was no significant difference in the fasting blood sugar, fasting insulin and HOMA-IR between the three arms.

**Predictors of response to ovulation**

[Figure 4](#F4){ref-type="fig"} depicts receiver operating characteristic (ROC) curve with low baseline LH as predictor for ovulation with area under curve (AUC) =0.619.

![Receiver operating characteristic curve demonstrating low baseline luteinizing hormone as predictor of ovulation](JHRS-7-255-g010){#F4}

[Figure 5](#F5){ref-type="fig"} depicts ROC curve with percentage weight loss as the best marker for ovulation with AUC = 0.839.

![Receiver operating characteristic curve demonstrating percentage weight loss as best marker for ovulation](JHRS-7-255-g011){#F5}

Subjects in orlistat and metformin group showed statistically significant response as compared to the control group (*P* - 0.001) in terms of folliculogenesis. However, the two drug arms namely orlistat and metformin were similar as far as their effect on folliculogenesis is concerned (*P* - 0.190).

**Side-effects**

Patients in the metformin group reported side-effects such as nausea, epigastric pain. However, those in orlistat group tolerated the drug well. Gastrointestinal symptoms were present in 6.7% of patients who received metformin and none of the orlistat group had any symptoms.

DISCUSSION {#sec1-3}
==========

Weight loss {#sec2-19}
-----------

In the present study, statistically significant weight loss in terms of weight, BMI, waist circumference and waist-hip ratio was achieved with the degree of decline being same in both metformin and orlistat arms (*P* - 0.418) compared to the control arm. It is similar to results in previous studies by Metwally *et al*.\[[@ref5]\] and Ghandi *et al*.\[[@ref6]\] as shown in [Table 7](#T7){ref-type="table"}.

###### 

Comparison of the outcome of the current study with that of Metwally *et al*. and Ghandi *et al*. studies

![](JHRS-7-255-g012)

The pilot study in 2005 by Jayagopal *et al*.\[[@ref7]\] demonstrated that those on orlistat showed more significant reduction in weight compared to metformin with *P* - 0.002 for orlistat versus 0.006 for metformin.

Ovulation rates {#sec2-20}
---------------

The result of the current study suggests that both orlistat and metformin can induce ovulation in overweight and obese PCOS women at similar rates (33.3% vs. 23.3%, *P* - 0.418). These results are consistent with previous studies by Metwally *et al*.\[[@ref5]\] and Ghandi *et al*.\[[@ref6]\]

The best predictor of ovulation according to the present and the previous study is percentage weight loss and a low concentration of baseline LH.

Androgen profile {#sec2-21}
----------------

Our study demonstrated a statistically significant fall in total serum testosterone levels and improvements in the FAI in both drug arms.

Similar to the results of present study Metwally *et al*.\[[@ref5]\] and Jayagopal *et al*.\[[@ref7]\] found a significant decrease in the values of total testosterone and FAI in both the orlistat and metformin group.

Lipid profile {#sec2-22}
-------------

In the current study treatment with orlistat produced significant change in the lipid parameters including significant fall in total cholesterol, LDL cholesterol and triglycerides (*P* \< 0.05), whereas subjects in metformin and control arm showed no change in lipid profile.

Insulin resistance {#sec2-23}
------------------

In the current study, none of the groups showed improvement in any of the biochemical parameters for assessing insulin resistance. Nevertheless, there was fall in levels of fasting blood sugar, fasting insulin and HOMA-IR in the metformin group but it did not reach the level of significance.

When plasminogen activator-1 (PAI-1) levels were analyzed in a study, orlistat did not show any reduction in PAI-1, compared with metformin. The reduction in circulating androgens during Metformin treatment might be implicated in this decline.\[[@ref11]\]

A study on 101 PCOS woman showed orlistat combined with lifestyle changes induces substantial weight loss in PCOS.\[[@ref12]\] However, emphasis on lifestyle changes when combined with anti-obesity agents, exert beneficial effects on the endocrine abnormalities of obese patients with PCOS and improve metabolic parameters.\[[@ref13]\] A study with, 24 weeks of orlistat with diet and physical exercise resulted in significant weight loss, improvement of hyperandrogenism and insulin sensitivity and increased anti-Müllerian hormone levels.\[[@ref14]\] The importance of lifestyle modification should be stressed before initiation of pharmacological intervention.\[[@ref15]\]

CONCLUSION {#sec1-4}
==========

However, all these studies including our study have given substantial evidence that both orlistat and metformin are more efficacious in reducing weight, and ovulation in obese PCOS patients compared to control thereby demonstrating the therapeutic potential of orlistat in PCOS. In addition, subjects in orlistat group showed significant improvement in lipid profile. However, orlistat has minimal side-effects and is better tolerated compared to metformin. Though there was no statistically significant difference in term of reduction of BMI, waist circumference and waist-hip ratio between orlistat and metformin groups, ovulation rates in both groups were comparable. The significant improvements observed in lipid profile including LDL, Triglycerides and total cholesterol at the end of 3 months, is an observation for reducing cardiovascular problems on long-term intake of orlistat.
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